Holen Sie sich die Stockscreener-App
0.95
1.69%
0.0158
Handel nachbörslich:
.96
0.01
+1.05%
Palatin Technologies Inc. Aktie (PTN) Neueste Nachrichten
Palatin Technologies, Inc. (AMEX:PTN) Q1 2025 Earnings Call Transcript - Insider Monkey
Palatin Technologies Inc (PTN) Quarterly 10-Q Report - Quartzy
Palatin Technologies Inc (PTN) Q1 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue ... - Yahoo Finance
Palatin Technologies Shifts Focus to Obesity Treatments - TipRanks
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results - Nasdaq
Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024 - BioSpace
Palatin Technologies Sets Q1 2025 Earnings Release for November 14 | PTN Stock News - StockTitan
Palatin Technologies (BUE:PTN) 9-Day RSI : N/A (As of Nov. 06, 2024) - GuruFocus.com
Palatin Technologies (BUE:PTN) 5-Year Dividend Growth Rate : 0.00% (As of Jun. 2024) - GuruFocus.com
Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024 - PR Newswire
HC Wainwright Reaffirms Buy Rating for Palatin Technologies (NYSEAMERICAN:PTN) - Defense World
Finansavisen - Finansavisen
Palatin Receives Notice of Non-Compliance from NYSE American - GuruFocus.com
Palatin Technologies, Inc. Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity - Marketscreener.com
Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones - GuruFocus.com
PTNPalatin Technologies, Inc. Latest Stock News & Market Updates - StockTitan
Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium - StockTitan
Palatin Presents Foundational Data on Novel and Highly Selective - GuruFocus.com
Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium – Company AnnouncementFT.com - Financial Times
Dry Eye Disease Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Palatin Technologies, Novaliq, mc2 therapeutics - The Globe and Mail
Palatin faces NYSE American non-compliance notice By Investing.com - Investing.com Australia
Palatin faces NYSE American non-compliance notice - Investing.com
Palatin Technologies (NYSEAMERICAN:PTN) Issues Quarterly Earnings Results - Defense World
Palatin Technologies, Inc. (AMEX:PTN) Q4 2024 Earnings Call Transcript - Insider Monkey
Palatin Technologies Inc. (PTN) is a good investment, but the stock may be undervalued - US Post News
Earnings call: Palatin highlights pipeline progress, asset sale in FY 2024 By Investing.com - Investing.com South Africa
Earnings call: Palatin highlights pipeline progress, asset sale in FY 2024 - Investing.com Canada
Palatin Technologies Inc (PTN) Q4 2024 Earnings Call Transcript Highlights: Strategic Moves and ... - Yahoo Finance
Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones - BioSpace
Palatin shares hold steady as analyst maintains buy rating and $17 target - Investing.com Canada
An Analysis of Palatin Technologies Inc. (PTN)’s Potential Price Growth - Knox Daily
PTN Stock: A Comprehensive Analysis and Forecast - The InvestChronicle
Palatin Technologies Inc (PTN) Q4 2024 Earnings Report Preview: What To Expect - GuruFocus.com
Stock Market Recap: Palatin Technologies Inc. (PTN) Concludes at 0.84, a -11.27 Surge/Decline - The Dwinnex
PTN underperforms with a -1.39 decrease in share price - US Post News
Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results - Marketscreener.com
Market Momentum: Palatin Technologies Inc. (PTN) Registers a -15.70 Decrease, Closing at 1.02 - The Dwinnex
Palatin Technologies (NYSEAMERICAN:PTN) Share Price Crosses Above 200-Day Moving Average of $0.00 - Defense World
Palatin Technologies stock hits 52-week low at $1.25 By Investing.com - Investing.com Australia
Palatin Technologies stock hits 52-week low at $1.25 - Investing.com India
Planet Fitness (NYSE:PLNT) Sets New 12-Month High at $84.69 - MarketBeat
Palantir Technologies Inc [PLTR] Records 200-Day SMA of $23.71 - Knox Daily
Palantir Stock Hits 52-Week Highs Thursday: What's Going On? - Benzinga
Pharvaris initiated with a Buy at JonesResearch - TipRanks
Pliant Therapeutics (NASDAQ:PLRX) Sees Strong Trading Volume - Defense World
Palantir Stock Is Skyrocketing. 1 Analyst Thinks It Has Another 38% Gain Ahead. - MSN
Palantir Technologies (NYSE:PLTR) Shares Up 0.6% - MarketBeat
Priority Technology (NASDAQ:PRTH) Hits New 52-Week High at $6.90 - Defense World
PRTH stock soars to 52-week high, touches $6.87 amid growth - Investing.com
PLRX’s 52-Week Rollercoaster: From $10.29 to $19.62 – What’s Next for Investors? - The InvestChronicle
Quest Partners LLC Purchases New Shares in Pulse Biosciences, Inc. (NASDAQ:PLSE) - Defense World
Arizona State Retirement System Boosts Stock Position in Photronics, Inc. (NASDAQ:PLAB) - Defense World
Priority technology executive sells shares worth over $61,000 By Investing.com - Investing.com Canada
Priority Technology (NASDAQ:PRTH) Shares Gap Up to $6.02 - MarketBeat
Pliant Therapeutics (NASDAQ:PLRX) Sees Large Volume Increase - MarketBeat
What is the investor’s view on Pliant Therapeutics Inc (PLRX)? - US Post News
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):